M
Michael Fiegl
Researcher at Ludwig Maximilian University of Munich
Publications - 111
Citations - 4814
Michael Fiegl is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Myeloid leukemia & Cancer. The author has an hindex of 31, co-authored 110 publications receiving 4276 citations. Previous affiliations of Michael Fiegl include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
Ismael Samudio,Romain Harmancey,Michael Fiegl,Hagop M. Kantarjian,Marina Konopleva,Borys Korchin,Kumar Kaluarachchi,William G. Bornmann,Seshagiri Duvvuri,Heinrich Taegtmeyer,Michael Andreeff +10 more
TL;DR: It is demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells to apoptosis induction by ABT-737, and evidence suggesting that FAO regulates the activity of Bak-dependent mitochondrial permeability transition is generated.
Journal ArticleDOI
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler,Klaus H. Metzeler,Tobias Herold,Tobias Herold,Maja Rothenberg-Thurley,Susanne Amler,Maria Cristina Sauerland,Dennis Görlich,Stephanie Schneider,Nikola P. Konstandin,Annika Dufour,Kathrin Bräundl,Kathrin Bräundl,Bianka Ksienzyk,Evelyn Zellmeier,Luise Hartmann,Luise Hartmann,Philipp A. Greif,Philipp A. Greif,Michael Fiegl,Marion Subklewe,Marion Subklewe,Stefan K. Bohlander,Utz Krug,Andreas Faldum,Wolfgang E. Berdel,Bernhard Wörmann,Thomas Büchner,Wolfgang Hiddemann,Wolfgang Hiddemann,Jan Braess,Karsten Spiekermann,Karsten Spiekermann +32 more
TL;DR: This study provides a comprehensive overview of the spectrum, clinical associations, and prognostic relevance of recurrent driver gene mutations in a large cohort representing a broad spectrum and age range of intensively treated AML patients.
Journal ArticleDOI
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy
Johannes Drach,Jutta Ackermann,Elke Fritz,Elisabeth Krömer,Rudolf Schuster,Heinz Gisslinger,Maria DeSantis,Niklas Zojer,Michael Fiegl,S. Roka,Judith Schuster,Renate Heinz,Heinz Ludwig,Heinz Huber +13 more
TL;DR: It is concluded that a p53 gene deletion, which can be identified by interphase FISH in almost a third of patients with newly diagnosed MM, is a novel prognostic factor predicting for short survival of MM patients treated with conventional-dose chemotherapy.
Journal ArticleDOI
Mitochondrial uncoupling and the Warburg effect: Molecular basis for the reprogramming of cancer cell metabolism
TL;DR: Intriguingly, leukemia cells cultured on bone marrow-derived stromal feeder layers are more resistant to chemotherapy, increase the expression of uncoupling protein 2, and decrease the entry of pyruvate into the Krebs cycle-without compromising the consumption of oxygen, suggesting a shift to the oxidation of nonglucose carbon sources to maintain mitochondrial integrity and function.
Journal ArticleDOI
Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry.
Magdalena Ligor,Tomasz Ligor,Amel Bajtarevic,Clemens Ager,Martin Pienz,Martin Klieber,H. Denz,Michael Fiegl,Wolfgang Hilbe,Wolfgang Weiss,Peter Lukas,Herbert Jamnig,Martin Hackl,Bogusław Buszewski,Wolfram Miekisch,Jochen K. Schubert,Anton Amann +16 more
TL;DR: The main achievement of the present work is the validated identification of compounds observed in exhaled breath of lung cancer patients, and this identification is indispensible for future work on the biochemical sources of these compounds and their metabolic pathways.